2005至2022年瑞士儿童与青少年蜱传脑炎疫苗接种覆盖率、疾病及疫苗效果评估:一项结合横断面分析与病例对照研究
该研究结合瑞士全国重复横断面调查与病例对照分析,评估2005至2022年0-17岁人群蜱传脑炎(TBE)疫苗接种覆盖率、疾病严重程度及疫苗效果。接种覆盖率从4.8%升至50.1%;不完全接种疫苗效果为66.2%,完全接种为90.8%,末次接种后10年内疫苗效果仍达83.9%。即使5岁以下儿童也可发生重症TBE,完全接种可提供长达10年的持久保护。
要点
- 2005至2022年瑞士0-17岁人群TBE疫苗接种覆盖率从4.8%升至50.1%。
- 不完全接种疫苗效果66.2%,完全接种90.8%,末次接种后10年内仍达83.9%。
- 即使5岁以下儿童也可发生重症TBE,完全接种可提供持久保护。
核心结论
- 即使5岁以下儿童也可发生重症蜱传脑炎(TBE)。
- 不完全接种和完全接种均能预防TBE的神经系统表现。
- 完全接种可提供长达10年的持久保护。
研究设计与样本
- 采用瑞士全国重复横断面调查(SNVCS)估计2005至2022年0-17岁人群疫苗接种覆盖率。
- 利用瑞士疾病监测系统数据确定2005至2022年TBE发病率和严重程度。
- 通过病例对照分析计算疫苗效果,将TBE病例与SNVCS对照进行匹配。
主要发现
- 研究期间疫苗接种覆盖率从4.8%(95%CI:4.1-5.5%)升至50.1%(95%CI:48.3-52.0%)。
- TBE病例报告的临床症状在各年龄组间相似。
- 与未接种者相比,不完全接种(1-2剂)和完全接种(≥3剂)病例发生神经系统受累的可能性较低。
- 不完全接种的疫苗效果为66.2%(95%CI:42.3-80.2),完全接种为90.8%(95%CI:87.7-96.4)。
- 末次接种后10年内疫苗效果仍高达83.9%(95%CI:69.0-91.7)。
关键数值与推荐
- 不完全接种(1-2剂)疫苗效果66.2%(95%CI:42.3-80.2)。
- 完全接种(≥3剂)疫苗效果90.8%(95%CI:87.7-96.4)。
- 末次接种后10年内疫苗效果83.9%(95%CI:69.0-91.7)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundTick-borne encephalitis (TBE) is a severe, vaccine-preventable viral infection of the central nervous system. Symptoms are generally milder in children and adolescents than in adults, though severe disease does occur. A better understanding of the disease burden and duration of vaccine-mediated protection is important for vaccination recommendations.AimTo estimate TBE vaccination coverage, disease severity and vaccine effectiveness (VE) among individuals aged 0-17 years in Switzerland.MethodsVaccination coverage between 2005 and 2022 was estimated using the Swiss National Vaccination Coverage Survey (SNVCS), a nationwide, repeated cross-sectional study assessing vaccine uptake. Incidence and severity of TBE between 2005 and 2022 were determined using data from the Swiss disease surveillance system and VE was calculated using a case-control analysis, matching TBE cases with SNVCS controls.ResultsOver the study period, vaccination coverage increased substantially, from 4.8% (95% confidence interval (CI): 4.1-5.5%) to 50.1% (95% CI: 48.3-52.0%). Reported clinical symptoms in TBE cases were similar irrespective of age. Neurological involvement was less likely in incompletely (1-2 doses) and completely (≥ 3 doses) vaccinated cases compared with unvaccinated ones. For incomplete vaccination, VE was 66.2% (95% CI: 42.3-80.2), whereas VE for complete vaccination was 90.8% (95% CI: 87.7-96.4). Vaccine effectiveness remained high, 83.9% (95% CI: 69.0-91.7) up to 10 years since last vaccination.ConclusionsEven children younger than 5 years can experience severe TBE. Incomplete and complete vaccination protect against neurological manifestations of the disease. Complete vaccination offers durable protection up to 10 years against TBE.
引用
- Zens KD, Altpeter E, Wymann MN, et al. A combined cross-sectional analysis and case-control study evaluating tick-borne encephalitis vaccination coverage, disease and vaccine effectiveness in children and adolescents, Switzerland, 2005 to 2022. Euro Surveill. 2024. PMID: 38699900. doi:10.2807/1560-7917.ES.2024.29.18.2300558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。